reviewed april 2026|next review october 2026|88 physicians psi has verified|40887 published studies
Osteocalcin (Uncarboxylated)
Osteocalcin is a 49-amino acid bone-derived peptide hormone produced by osteoblasts that established the Karsenty paradigm of bone as an endocrine organ, with the uncarboxylated form circulating to regulate glucose metabolism, testosterone production, and cognitive function in animal models.
Evidence landscape: 40887 published studies
Published studies span skeletal endocrinology, metabolism, and neuroendocrine biology. Strong animal model evidence with supporting human observational data.
- 26 Human
- 140 Animal
- 34 Reviews
- 40687 Other research
Not FDA-approved as a therapeutic. Osteocalcin is used clinically as a bone turnover biomarker. No therapeutic development programs are registered for the hormone itself.
Not available as a therapeutic product. Used as a clinical biomarker for bone metabolism. Exercise naturally increases circulating uncarboxylated osteocalcin levels.
Osteocalcin is a naturally occurring (the body's own) bone-derived hormone. The carboxylated form binds hydroxyapatite in bone matrix, while the uncarboxylated form enters circulation and acts on pancreas, muscle, brain, and testes through the GPRC6A receptor.
PSI Assessment
The idea that bones are just structural scaffolding changed fundamentally in 2007 when Gerard Karsenty's laboratory demonstrated that a bone protein called osteocalcin functions as a hormone connecting the skeleton to metabolism, fertility, and brain function. The uncarboxylated form enters the bloodstream and signals through the GPRC6A receptor in the pancreas, muscle, brain, and testes. Exercise increases circulating levels. The animal data is compelling and reproducible. What remains missing is the interventional human trial that would confirm whether this biology can be therapeutically exploited.
Established bone as an endocrine organ. Uncarboxylated osteocalcin links skeletal health to metabolism, testosterone, and cognition in animal models. Human interventional data is absent.
The mechanism involves two forms of the same protein with different functions. Carboxylated osteocalcin binds hydroxyapatite in bone, serving as a structural matrix protein. Uncarboxylated osteocalcin (released during bone resorption) enters circulation and acts as a hormone through the GPRC6A receptor. In pancreatic beta cells, it enhances insulin secretion and proliferation. In muscle, it promotes glucose uptake during exercise. In the hippocampus, it crosses the blood-brain barrier and promotes serotonin, dopamine, and BDNF synthesis. In Leydig cells, it stimulates testosterone production.
What the evidence supports
Uncarboxylated osteocalcin functions as a bone-derived hormone linking the skeleton to glucose metabolism, testosterone production, and brain function in animal models. The Karsenty laboratory paradigm establishing bone as an endocrine organ is supported by multiple independent research groups. Human observational data shows consistent associations between osteocalcin levels and metabolic health markers.
What is not yet established
Whether exogenous osteocalcin administration improves metabolic outcomes in humans. Controlled human interventional trials are absent. Whether the dramatic endocrine effects observed in mouse models translate to human physiology at a therapeutically meaningful level. No clinical development program exists.
Research Evidence
The findings below cover the metabolic, reproductive, and cognitive dimensions of osteocalcin research across animal and human studies.
Evidence by condition
Evidence dimensions across metabolic, reproductive, and cognitive research. Animal models have the deepest evidence. Human data is observational only.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Metabolic Regulation | ||||
| Testosterone Production | ||||
| Cognitive Function | ||||
| Bone Metabolism Biomarker |
The 2007 landmark study from the Karsenty laboratory established that osteocalcin-deficient mice develop glucose intolerance, insulin resistance, and obesity, proving that bone-derived osteocalcin regulates metabolism.
This finding launched the field of skeletal endocrinology. Multiple independent groups have replicated the metabolic phenotype in osteocalcin-deficient animal models.
Uncarboxylated osteocalcin stimulates testosterone production in Leydig cells through GPRC6A receptor activation and promotes cognitive function by enhancing BDNF, serotonin, and dopamine synthesis in the hippocampus.
These fertility and cognitive dimensions extend the endocrine paradigm beyond metabolism. Human observational studies show associations between osteocalcin levels and testosterone, but interventional data is lacking.
Exercise increases circulating uncarboxylated osteocalcin in humans, and osteocalcin levels decline with age in correlation with metabolic deterioration.
The exercise connection suggests osteocalcin may mediate some metabolic benefits of physical activity. The age-related decline parallels metabolic dysfunction but causation versus correlation is not established in humans.
26 Human|140 Animal|34 Reviews
View all 40887 indexed studiesHow Osteocalcin (Uncarboxylated) Works
Uncarboxylated osteocalcin is a naturally occurring (the body's own) 49-amino acid bone-derived hormone. It signals through the GPRC6A receptor in peripheral tissues to regulate glucose metabolism, testosterone production, and cognitive function.
Bones produce osteocalcin, which helps regulate blood sugar, testosterone, and brain function.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Undercarboxylated osteocalcin binds GPRC6A in beta cells, Leydig cells, and hippocampal neurons.
What is Osteocalcin (Uncarboxylated) being studied for?
Researchers are studying Osteocalcin (Uncarboxylated) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Osteocalcin (Uncarboxylated) overall. This means a compound can have human studies for one condition but only animal data for another.
Metabolic Regulation
·Human TrialsUncarboxylated osteocalcin enhances insulin secretion and beta cell proliferation in animal models (animal research). Human observational data shows consistent associations between osteocalcin levels and glucose metabolism markers.
Limitations: No interventional human trial has tested exogenous osteocalcin for metabolic benefit. The dramatic metabolic effects in mice may not translate proportionally to humans.
Testosterone Production
·Animal StudiesOsteocalcin stimulates Leydig cell testosterone synthesis through GPRC6A receptor activation in animal models (animal research). Human observational studies show correlation between osteocalcin levels and serum testosterone.
Limitations: No interventional human data exists. Whether exogenous osteocalcin could meaningfully raise testosterone in humans is unknown.
Cognitive Function
·Animal StudiesOsteocalcin crosses the blood-brain barrier and promotes BDNF, serotonin, and dopamine synthesis in the hippocampus in animal models (animal research). Osteocalcin-deficient mice show anxiety-like behavior and memory impairment.
Limitations: Human cognitive effects are inferred from animal data only. No human study has tested osteocalcin administration for cognitive outcomes.
Bone Metabolism Biomarker
·Human TrialsOsteocalcin is an established clinical biomarker for bone formation and turnover. Used routinely in the assessment of bone metabolic disorders.
Limitations: The biomarker application is well-validated but distinct from the endocrine hormone research. Biomarker use does not require the endocrine paradigm to be therapeutically exploited.
Safety and Regulatory Status
FDA Status: Not FDA-approved as a therapeutic. Used clinically as a bone turnover biomarker only. No clinical development program exists for osteocalcin hormone therapy.
Availability: Not available as a therapeutic product. Research-grade material available for laboratory use. Exercise is the primary physiological method to increase circulating levels.
Class context: Osteocalcin is a naturally occurring (the body's own) hormone produced by osteoblasts during bone formation. The endocrine functions are a recent discovery (2007). The gap between biomarker use and therapeutic hormone application has not been bridged in clinical medicine.
Osteocalcin is a naturally occurring (the body's own) bone-derived hormone with no therapeutic formulation. Safety considerations are theoretical since no exogenous administration studies have been conducted in humans.
Questions and Comparisons
Questions the evidence raises for a Osteocalcin (Uncarboxylated) discussion.
Comparison and Related Research
Osteocalcin is compared with other metabolic hormones and mitochondrial-derived peptides in the longevity research space.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Landmark study demonstrating that the bone-derived hormone osteocalcin acts as an endocrine regulator of energy metabolism. Mouse models showed that undercarboxylated osteocalcin promotes insulin secretion from pancreatic beta cells and improves glucose tolerance, establishing bone as a metabolically active endocrine organ.Lee NK et al., 2007 in Cell. View on PubMed
- 2.Cross-sectional analysis of 380 adults examining the relationship between circulating osteocalcin and metabolic markers. Higher serum osteocalcin levels were associated with lower fasting glucose, lower insulin resistance (HOMA-IR), and lower body fat percentage, supporting the hormone's role in metabolic regulation in humans.Pittas AG et al., 2009 in J Clin Endocrinol Metab. View on PubMed
- 3.Prospective study tracking osteocalcin levels in overweight and obese adults undergoing caloric restriction with exercise. Increases in osteocalcin were positively correlated with improvements in insulin sensitivity, suggesting a functional link between bone turnover and glucose metabolism during weight loss interventions.Fernandez-Real JM et al., 2009 in J Clin Endocrinol Metab. View on PubMed
- 4.Population-based study of 1,423 participants showing that lower serum osteocalcin levels were independently associated with metabolic syndrome. The association held after adjusting for age, BMI, and renal function, reinforcing the clinical relevance of osteocalcin as a biomarker for cardiometabolic health.Hwang YC et al., 2009 in Diabetes Metab Res Rev. View on PubMed
- 5.Clinical study in 148 patients with type 2 diabetes evaluating the relationship between osteocalcin and glucose homeostasis. Serum osteocalcin was positively correlated with insulin sensitivity (measured by HOMA) and beta-cell function, suggesting a role in glycemic control even in an established diabetic population.Kanazawa I et al., 2011 in J Clin Endocrinol Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.